Statistically Significant Phase II Clinical Results For Prophylactic Use Of rhITF In Mucositis Published In Journal Of Clinical Oncology

FRAMINGHAM, MA -- Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy." rhITF oral spray is being developed for the treatment and prevention of oral mucositis (OM). Oral mucositis can be a serious, non-hematologic oral complication of high-dose systemic chemotherapy and radiation-based anti-cancer treatment...